ABIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:
We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.
Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
As of today (2024-04-25), ARCA biopharma's share price is $3.63. ARCA biopharma's GF Value is $0.00. Therefore, ARCA biopharma's Price-to-GF-Value for today is .
Based on the relationship between the current stock price and the GF Value, GuruFocus believes ARCA biopharma is Not Valued.
ARCA biopharma (NAS:ABIO) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) There is only a sufficient margin of safety when the stock is undervalued.
ARCA biopharma's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 3.63 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of ARCA biopharma's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
James P Flynn | director | 41 HARRIS CT, DANVILLE CA 94526 |
Funicular Funds, Lp | 10 percent owner, other: See Footnote 1 | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Funicular Fund, Lp | other: See Footnote 1 | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Jacob Ma-weaver | other: See Remarks | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Christopher David Ozeroff | officer: S.V.P., General Counsel | 8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021 |
Robert E Conway | director | C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021 |
C. Jeffrey Dekker | officer: Chief Financial Officer | 10170 CHURCH RANCH WAY, WESTMINSTER CO 80021 |
Thomas A Keuer | officer: Chief Operating Officer | C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021 |
Brian L. Selby | officer: VP, Finance | 11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020 |
Venrock Healthcare Capital Partners Lp | 10 percent owner | 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036 |
Scott D Sandell | 10 percent owner | |
David M Mott | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Joshua Makower | 10 percent owner | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Forest Baskett | 10 percent owner | |
Peter J Barris | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-02-2022
By sperokesalga sperokesalga • 02-24-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 06-25-2022
By GuruFocusNews GuruFocusNews • 04-18-2022
By GuruFocusNews GuruFocusNews • 06-05-2022
By GlobeNewswire • 07-21-2023
By Don Li2 Don Li2 • 11-09-2021
By Value_Insider Value_Insider • 10-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.